Related Experiment Video

Updated: Apr 7, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K

Small molecule and peptide therapies for chronic heart failure: a patent review (2011 - 2014)

Brian Raymer1, David Ebner1

  • 1a Cardiovascular, Metabolic, and Endocrine Diseases Chemistry, Pfizer Worldwide Research and Development , Cambridge, MA, USA +1 617 551 3414 ; +1 617 551 3082 ; brian.raymer@pfizer.com.

Expert Opinion on Therapeutic Patents
|July 16, 2015
PubMed

Insights

New small molecule and peptidic agents offer hope for chronic heart failure (CHF) patients. Research focuses on novel therapies targeting the renin-angiotensin-aldosterone system and inotropic agents, addressing a significant unmet medical need.

Area of Science:

  • Cardiovascular Pharmacology
  • Drug Discovery
  • Translational Medicine

Background:

  • Chronic heart failure (CHF) impairs cardiac function, leading to symptoms like fluid retention, dyspnea, and fatigue.
  • Current treatments manage hypoperfusion via the renin-angiotensin-aldosterone and sympathetic nervous systems.
  • Therapies aim to reverse cardiac remodeling and prevent arrhythmias.

Purpose of the Study:

  • To review small molecule and peptidic agents for CHF treatment.
  • To analyze patents published between 2011 and 2014.
  • To identify emerging therapeutic targets for CHF.

Main Methods:

  • Literature review of patents related to CHF therapies.
  • Categorization of agents by therapeutic target: inotropic agents, ventricular remodeling, diuretics, and renin-angiotensin-aldosterone system.
  • Analysis of recent advancements in CHF drug development.

Main Results:

  • The renin-angiotensin-aldosterone system remains a key focus for new CHF therapies.
  • Emerging inotropic agents show promise.
  • Several novel therapeutic approaches are under investigation.

Conclusions:

  • Chronic heart failure presents a substantial unmet medical need.
  • The renin-angiotensin-aldosterone system pathway is a significant source of new CHF therapies.
  • Emerging inotropic therapies and other approaches indicate a promising future for CHF treatment.
Abstract

Keywords:
chronic heart failurediureticsinotropesrenin–angiotensin–aldosterone systemventricular remodeling

More Related Videos

Gene Transfer for Ischemic Heart Failure in a Preclinical Model07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.5K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.5K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
557
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
588
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
72
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.2K